The Discounted Cash Flow (DCF) valuation of Dicerna Pharmaceuticals Inc (DRNA) is (143.72) USD. With the latest stock price at 38.22 USD, the upside of Dicerna Pharmaceuticals Inc based on DCF is -476.0%.
Based on the latest price of 38.22 USD and our DCF valuation, Dicerna Pharmaceuticals Inc (DRNA) is a sell. selling DRNA stocks now will result in a potential gain of 476.0%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 5.7% - 7.5% | 6.6% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (535.46) - (83.71) | (143.72) |
| Upside | -1501.0% - -319.0% | -476.0% |